Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Severe vaginal bleeding associated with recombinant interferon beta-1B

L A Pakulski1, L M DiMarco

  • 1Regional Health Services, Hamot Health Foundation, Erie, PA 16550, USA.

The Annals of Pharmacotherapy
|January 1, 1997
PubMed
Summary

Severe vaginal bleeding, a rare complication, was observed in a multiple sclerosis patient treated with interferon beta-1b (IFN-beta). Discontinuation of IFN-beta led to cessation of bleeding, highlighting a potential adverse effect of this multiple sclerosis therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A rapid digestive technique to expose networks of vascular elastic fibers for SEM observation.

Stain technologyยท1984
See all related articles

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Interferon beta-1b (IFN-beta) is a common disease-modifying therapy for MS.

Observation:

  • A 19-year-old female with MS experienced severe vaginal bleeding after dose escalation of IFN-beta.
  • The patient presented with severe anemia (hemoglobin 3.9 g/dL) requiring hospitalization and blood transfusion.

Findings:

  • IFN-beta treatment was discontinued, and the patient received conjugated estrogens.
  • The vaginal bleeding ceased following the discontinuation of IFN-beta, suggesting a probable association.

Implications:

  • While mild menstrual irregularities are known, severe vaginal bleeding is a rare but significant adverse event associated with IFN-beta.

Related Experiment Videos

  • Clinicians should consider IFN-beta as a potential cause of severe menstrual disorders in MS patients and monitor for such complications.